Cardiac software developer Myocardial Solutions has raised $6.7 million from 22 investors in an equity offering that began in mid-December.
The company’s software is designed to measure heart strain, giving physicians a window into a patient’s heart function. The MyoStrain report is generated through magnetic resonance imaging.
The report provides ejection fraction, mass and volume measures. The software can also give regional measures of heart strain, evaluating 37 areas of the left ventricle’s function.
According to the company’s website, its software can help identify asymptomatic patients with heart dysfunction.
Myocardial Solutions touts that its software has been used in over 70 major medical research centers around the globe and “is established as the gold standard for strain measurement.”
MyoStrain has CE Mark clearance in the E.U. and the company is working on landing 510(k) clearance with the FDA.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.